Review





Similar Products

cd34 antibody  (NSJ Bioreagents)
99
NSJ Bioreagents cd34 antibody
Cd34 Antibody, supplied by NSJ Bioreagents, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34/custom%40v2067%4042355608?v=NSJ+Bioreagents
Average 99 stars, based on 1 article reviews
cd34 antibody - by Bioz Stars, 2026-07
99/100 stars
  Buy from Supplier
cd34 microbead kit, human  (Miltenyi Biotec)
97
Miltenyi Biotec cd34 microbead kit, human
Cd34 Microbead Kit, Human, supplied by Miltenyi Biotec, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34/custom%40130-046-703%4042321078?v=Miltenyi+Biotec
Average 97 stars, based on 1 article reviews
cd34 microbead kit, human - by Bioz Stars, 2026-07
97/100 stars
  Buy from Supplier
humanized cd34 nsg female mice  (Jackson Laboratory)
86
Jackson Laboratory humanized cd34 nsg female mice
BNT351 suppresses viremia in HIV-1-infected humanized <t>CD34</t> + NSG mice without selecting for resistant viral variants (A) Experiment scheme: HIV-1 YU2 -infected CD34 + humanized NSG mice ( n = 7/group) received subcutaneous (SC) injections of BNT351 (1 mg loading dose, followed by 0.5 mg every 3–4 days for 8 weeks) or DPBS (control) on the same days. Plasma viral loads were monitored once weekly for 17 weeks, and plasma SGS was performed at baseline and on day 84, 91, or 98. (B) RT-qPCR was used to measure plasma viral loads. HIV-1 RNA plasma copies (top) and log10 viral load changes compared with baseline (bottom) are shown. Gray shading indicates the BNT351 treatment period. Data points in white indicate viral loads below lower limit of quantification (LLOQ = 774 copies/mL). For visualization in the absolute copy number plots, viral loads <LLOQ were assigned an arbitrary value so that lines and icons of individual mice remained distinguishable. For calculation and visualization of log10 changes compared to baseline, a value of 773 was assigned to all viral load measurements <LLOQ. Red lines show average log 10 viral load change compared with baseline. (C) Plasma env sequences obtained by SGS in individual mice after viral rebound (day 84, 91, or 98). Blue boxes highlight key regions of potential escape from CD4 binding site antibodies. Bars indicate amino acid substitutions relative to HIV-1 YU2 wild type already identified at baseline in the same mouse (black) or only identified after rebound (red). A selection of SGS-derived env sequences containing indicated mutations were produced as pseudoviruses and their sensitivity to BNT351 tested in a pseudovirus neutralization test with TZM-bl reporter cells. IC 50 -fold changes to wild-type sequence <2.5 indicate BNT351 sensitivity. Note: the x-axis numbering is according to HIV-1 YU2 strain, while the substitutions are numbered according to the (conventional) HIV-1 HXB2 numbering scheme.
Humanized Cd34 Nsg Female Mice, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34/pmc13276592-345-0-11?v=Jackson+Laboratory
Average 86 stars, based on 1 article reviews
humanized cd34 nsg female mice - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier
rabbit anti cd34  (Servicebio Inc)
86
Servicebio Inc rabbit anti cd34
BNT351 suppresses viremia in HIV-1-infected humanized <t>CD34</t> + NSG mice without selecting for resistant viral variants (A) Experiment scheme: HIV-1 YU2 -infected CD34 + humanized NSG mice ( n = 7/group) received subcutaneous (SC) injections of BNT351 (1 mg loading dose, followed by 0.5 mg every 3–4 days for 8 weeks) or DPBS (control) on the same days. Plasma viral loads were monitored once weekly for 17 weeks, and plasma SGS was performed at baseline and on day 84, 91, or 98. (B) RT-qPCR was used to measure plasma viral loads. HIV-1 RNA plasma copies (top) and log10 viral load changes compared with baseline (bottom) are shown. Gray shading indicates the BNT351 treatment period. Data points in white indicate viral loads below lower limit of quantification (LLOQ = 774 copies/mL). For visualization in the absolute copy number plots, viral loads <LLOQ were assigned an arbitrary value so that lines and icons of individual mice remained distinguishable. For calculation and visualization of log10 changes compared to baseline, a value of 773 was assigned to all viral load measurements <LLOQ. Red lines show average log 10 viral load change compared with baseline. (C) Plasma env sequences obtained by SGS in individual mice after viral rebound (day 84, 91, or 98). Blue boxes highlight key regions of potential escape from CD4 binding site antibodies. Bars indicate amino acid substitutions relative to HIV-1 YU2 wild type already identified at baseline in the same mouse (black) or only identified after rebound (red). A selection of SGS-derived env sequences containing indicated mutations were produced as pseudoviruses and their sensitivity to BNT351 tested in a pseudovirus neutralization test with TZM-bl reporter cells. IC 50 -fold changes to wild-type sequence <2.5 indicate BNT351 sensitivity. Note: the x-axis numbering is according to HIV-1 YU2 strain, while the substitutions are numbered according to the (conventional) HIV-1 HXB2 numbering scheme.
Rabbit Anti Cd34, supplied by Servicebio Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/cd34/pm42316874-46-57-60?v=Servicebio+Inc
Average 86 stars, based on 1 article reviews
rabbit anti cd34 - by Bioz Stars, 2026-07
86/100 stars
  Buy from Supplier

Image Search Results


BNT351 suppresses viremia in HIV-1-infected humanized CD34 + NSG mice without selecting for resistant viral variants (A) Experiment scheme: HIV-1 YU2 -infected CD34 + humanized NSG mice ( n = 7/group) received subcutaneous (SC) injections of BNT351 (1 mg loading dose, followed by 0.5 mg every 3–4 days for 8 weeks) or DPBS (control) on the same days. Plasma viral loads were monitored once weekly for 17 weeks, and plasma SGS was performed at baseline and on day 84, 91, or 98. (B) RT-qPCR was used to measure plasma viral loads. HIV-1 RNA plasma copies (top) and log10 viral load changes compared with baseline (bottom) are shown. Gray shading indicates the BNT351 treatment period. Data points in white indicate viral loads below lower limit of quantification (LLOQ = 774 copies/mL). For visualization in the absolute copy number plots, viral loads <LLOQ were assigned an arbitrary value so that lines and icons of individual mice remained distinguishable. For calculation and visualization of log10 changes compared to baseline, a value of 773 was assigned to all viral load measurements <LLOQ. Red lines show average log 10 viral load change compared with baseline. (C) Plasma env sequences obtained by SGS in individual mice after viral rebound (day 84, 91, or 98). Blue boxes highlight key regions of potential escape from CD4 binding site antibodies. Bars indicate amino acid substitutions relative to HIV-1 YU2 wild type already identified at baseline in the same mouse (black) or only identified after rebound (red). A selection of SGS-derived env sequences containing indicated mutations were produced as pseudoviruses and their sensitivity to BNT351 tested in a pseudovirus neutralization test with TZM-bl reporter cells. IC 50 -fold changes to wild-type sequence <2.5 indicate BNT351 sensitivity. Note: the x-axis numbering is according to HIV-1 YU2 strain, while the substitutions are numbered according to the (conventional) HIV-1 HXB2 numbering scheme.

Journal: iScience

Article Title: Preclinical assessment of broadly neutralizing HIV-1 antibody BNT351 with optimized pharmacokinetics and potent antiviral activity

doi: 10.1016/j.isci.2026.116022

Figure Lengend Snippet: BNT351 suppresses viremia in HIV-1-infected humanized CD34 + NSG mice without selecting for resistant viral variants (A) Experiment scheme: HIV-1 YU2 -infected CD34 + humanized NSG mice ( n = 7/group) received subcutaneous (SC) injections of BNT351 (1 mg loading dose, followed by 0.5 mg every 3–4 days for 8 weeks) or DPBS (control) on the same days. Plasma viral loads were monitored once weekly for 17 weeks, and plasma SGS was performed at baseline and on day 84, 91, or 98. (B) RT-qPCR was used to measure plasma viral loads. HIV-1 RNA plasma copies (top) and log10 viral load changes compared with baseline (bottom) are shown. Gray shading indicates the BNT351 treatment period. Data points in white indicate viral loads below lower limit of quantification (LLOQ = 774 copies/mL). For visualization in the absolute copy number plots, viral loads

Article Snippet: Humanized CD34 + NSG female mice (NOD.Cg-Prkdc scid Il2rg tm1Wjl /SzJ, JAX strain #005557) engrafted with human cord blood-derived CD34 + hematopoietic stem cells) were purchased from The Jackson Laboratory and maintained at the Decentralized Animal Husbandry Network ( Dezentrales Tierhaltungsnetzwerk ) of the University of Cologne under specific pathogen-free (SPF) conditions until the start of experiment (HIV-1 challenge), when they were moved to an S3∗∗ facility.

Techniques: Infection, Control, Clinical Proteomics, Quantitative RT-PCR, Binding Assay, Selection, Derivative Assay, Produced, Neutralization, Sequencing